| Cathodal iontophoresis of treprostinil and iloprost induces a sustained increase in cutaneous flux in rats. | |
| | |
MedLine Citation:
|
PMID: 20860718 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND PURPOSE: The treatment of scleroderma-related digital ulcers is still a therapeutic challenge. The most effective drugs are prostacyclin analogues. However, their usage is limited to an intravenous route of administration and by their frequent side effects. The objective of this study was to test whether treprostinil, iloprost and epoprostenol can induce sustained vasodilatation in rats when delivered locally using cutaneous iontophoresis. EXPERIMENTAL APPROACH: Treprostinil, iloprost and epoprostenol were delivered by cathodal and anodal iontophoresis onto the hindquarters of anaesthesized rats (n= 8 for each group). Skin blood flow was quantified using laser Doppler imaging and cutaneous tolerance was assessed from day 0 to day 3. KEY RESULTS: Cathodal but not anodal iontophoresis of treprostinil (6.4 mM), iloprost (0.2 mM) and epoprostenol (1.4 mM) induced a significant and sustained increase in cutaneous blood flow. The effects of treprostinil and iloprost were significantly different from those of treprostinil vehicle. Only weak effects were observed when both drugs were applied locally without current. Skin resistance was unchanged in areas treated with prostacyclin analogues. Finally, skin tolerance was good, with no evidence of epidermal damage. CONCLUSIONS AND IMPLICATIONS: Cathodal iontophoresis of treprostinil and iloprost increases cutaneous blood flow with a good local tolerance. The effects of cathodal iontophoresis of these drugs should be investigated in humans, as they could have potential as new local therapies for digital ulcers in patients with scleroderma. |
| | |
Authors:
|
S Blaise; M Roustit; C Millet; C Ribuot; J Boutonnat; J L Cracowski |
Related Documents
:
|
18458938 - Ex vivo method to visualize and quantify vascular networks in native and tissue enginee... 2805658 - Percutaneous absorption of 3 organic solvents in the guinea pig (i). effect of physical... 20471788 - Hyperspectral imaging and ankle: brachial indices in peripheral arterial disease. 6236158 - Spatial and temporal variations in human skin blood flow. 18520548 - Global cerebral hypoperfusion in a patient with transient global amnesia. 16756598 - Comparison of prevalence rates of microbiological markers between bone/tissue donations... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: British journal of pharmacology Volume: 162 ISSN: 1476-5381 ISO Abbreviation: Br. J. Pharmacol. Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-01-13 Completed Date: 2011-07-26 Revised Date: 2012-02-01 |
Medline Journal Info:
|
Nlm Unique ID: 7502536 Medline TA: Br J Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 557-65 Citation Subset: IM |
Copyright Information:
|
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society. |
Affiliation:
|
Inserm ERI17, Grenoble Medical School, University Grenoble 1, Grenoble, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Cutaneous Animals Antihypertensive Agents / administration & dosage*, adverse effects, therapeutic use Electrodes Epoprostenol / administration & dosage*, adverse effects, analogs & derivatives*, therapeutic use Hemodynamics Humans Iloprost / administration & dosage*, adverse effects, therapeutic use Iontophoresis* Male Nitroprusside / administration & dosage Rats Rats, Wistar Skin / drug effects* |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/treprostinil; 15078-28-1/Nitroprusside; 35121-78-9/Epoprostenol; 78919-13-8/Iloprost |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective,...
Next Document: Construction and validation of the quality of life measure for dentine hypersensitivity (DHEQ).